TITLE

Pfizer, Battelle Join Up

PUB. DATE
September 2000
SOURCE
Chemical Market Reporter;09/25/2000, Vol. 258 Issue 13, p52
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Deals with the agreement between Pfizer Inc. and Battelle Pulmonary Therapeutics to develop drug products to treat pulmonary and systematic diseases. Terms of the agreement.
ACCESSION #
3609151

 

Related Articles

  • Pharma: Other News To Note.  // BioWorld Today;11/5/2013, Vol. 24 Issue 213, p14 

    This section offers news briefs on the pharmaceutical industry as of November 2013 including a partnership between Juvenile Diabetes Research Foundation (JDRF) and Centers for Therapeutic Innovation of Pfizer Inc. and the availability of the drug Epaned from Silvergate Pharmaceuticals Inc. for...

  • Pfizer, GSK Report on Research Ties.  // Chain Drug Review;4/25/2011, Vol. 33 Issue 8, p220 

    The article reports on the insights of Pfizer Inc. and GlaxoSmithKline (GSK) regarding the significant role played by research and development partnership in the U.S. health care industry.

  • BATTELLE SIGNS RESEARCH AGREEMENT WITH EIFFEL TECHNOLOGIES.  // Worldwide Biotech;Feb2002, Vol. 14 Issue 2, p6 

    Focuses on the research agreement between Battelle Pulmonary Therapeutics Inc. and Eiffel Research & Development Pty. Ltd. on electrohydrodynamic and pulmonary delivery device.

  • Drug Cloud.  // Technology Review;Jul/Aug2000, Vol. 103 Issue 4, p20 

    Informs that Battelle Pulmonary Therapeutics is aiming to deliver inhalable drugs more efficiently with `electrohydrodynamic' or EHD, aerosol technology. Use of voltage, rather than pressure, to create a `soft cloud' of aerosolized drug; Valuable against respiratory diseases and infections.

  • Infostop.  // Medical Device Technology;Jan/Feb2002, Vol. 13 Issue 1, p82 

    Reports developments in the medical instruments industry in Great Britain as of February 2002. Acquisition of Gammaster Group by Isotron; Details on the agreement between Bespak and Battelle Pulmonary Therapeutics; Investment of PAL Extrusions in invasive and external tubing products.

  • pSivida, in joint research effort with Pfizer, to get up to $155M.  // Medical Device Daily;4/5/2007, Vol. 11 Issue 65, p1 

    The article reports on the collaborative research and license agreement of Perth, Australia-based pSivida with Pfizer, for pSivida's controlled drug delivery technologies including the Medidur technology in ophthalmic applications. pSivida will receive up to $155 million in development and...

  • Adimab's Antibody Platform Nabs 2 Deals.  // Bioworld Week;12/21/2009, Vol. 17 Issue 51, p5 

    The article reports on the two new additional partnerships of Adimab Inc. for its yeast-based antibody research and development in the U.S. Accordingly, Adimab's co-founder Tillman Gerngross has said that the partnerships include one with Pfizer Inc. and another with an undisclosed company....

  • Breeding profits. Carmichael, Helen // European Chemical News;3/7/2005, Vol. 82 Issue 2137, p24 

    Discusses the significance of the collaboration of biotechnology company Codexis with pharmaceutical companies to develop biocatalysts for pharmaceutical patent protection and streamline processes. Factors that drove the company to specialize in pharmaceuticals; Advantages of MolecularBreeding;...

  • Nektar Halts Talks Over Exubera Cancer Concerns.  // Bioworld Week;4/14/2008, Vol. 16 Issue 15, p4 

    The article reports that Nektar Therapeutics Inc. will cease its spending and partnership talks for Exubera after a new analysis of clinical trial data which revealed an increased risk of lung cancer. It mentions that there were six newly diagnosed cases of primary lung malignancies among...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics